Latest HER2/neu Stories
OXFORD, England and SAN JOSE, May 7, 2014 /PRNewswire/ -- Oxford BioTherapeutics, an international biotechnology company focused on the development of innovative antibody-drug
Improved Overall Survival and Delayed Disease Progression are the Greatest Unmet Needs in this Population, According to Findings from Decision Resources Group BURLINGTON, Mass., April 10, 2014
NEW YORK, April 9, 2014 /PRNewswire/ -- The CementBloc, a leading healthwellness communications company headquartered in New York City, has been named a finalist in three out of ten categories
In an innovative clinical trial led by UC San Francisco, the experimental drug neratinib along with standard chemotherapy was found to be a beneficial treatment for some women with newly diagnosed, high-risk breast cancer.
Active research in breast cancer is producing novel targeted drugs at a rapid pace. Thousand Oaks, California (PRWEB) April 03, 2014 As the Cancer society
Dartmouth researchers at its Norris Cotton Cancer Center have compiled a review of the role that information gathered through genetic testing plays in the diagnosis and treatment of breast cancer.
Perjeta and Kadcyla are Reshaping the Treatment Algorithm for Patients with HER2-Positive Breast Cancer, According to Findings from Decision Resources Group BURLINGTON, Mass., March 25, 2014
DUBLIN, March 25, 2014 /PRNewswire/ -- Research and Markets ( http://www.researchandmarkets.com/research/czqbv2/investigation) has announced the addition of the "Investigation
- Growing in low tufty patches.